Like pls_老虎社区_美港股上老虎

2021-06-22

Like pls

Bionano Genomics: Did Reddit Squirrels Find a Nut?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":129306379,"tweetId":"129306379","gmtCreate":1624356108091,"gmtModify":1634007363027,"author":{"id":3562110654160486,"idStr":"3562110654160486","authorId":3562110654160486,"authorIdStr":"3562110654160486","name":"Angelinetang","avatar":"https://static.tigerbbs.com/db70c1a81c4a4398c4b43ef2d5c8c35d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like pls</body></html>","htmlText":"<html><head></head><body>Like pls</body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/129306379","repostId":1128318249,"repostType":4,"repost":{"id":"1128318249","kind":"news","pubTimestamp":1624355985,"share":"https://www.laohu8.com/m/news/1128318249?lang=&edition=full","pubTime":"2021-06-22 17:59","market":"us","language":"en","title":"Bionano Genomics: Did Reddit Squirrels Find a Nut?","url":"https://stock-news.laohu8.com/highlight/detail?id=1128318249","media":"InvestorPlace","summary":"BNGO stock has been pushed this year by both Wall Street pros and meme stock amateurs.\n\nWhenever I s","content":"<blockquote>\n BNGO stock has been pushed this year by both Wall Street pros and meme stock amateurs.\n</blockquote>\nWhenever I see a stock trending on ther/WallStreetBetssubreddit, I get suspicious. Anyone can post there. They can say anything. There’s the reputation for pushing short-squeezes on failing companies. There’s just no credibility.\n<img src=\"https://static.tigerbbs.com/68745a7c8e4a800f76911b7245e9f8e6\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Marcus Krauss / Shutterstock.com\nCase in point, a small company calledBionano Genomics(NASDAQ:BNGO), which in February gota push from the WSB crowd. It started as BNGO stock was selling at about $10 a share. It quickly jumped to $15. Then it fell, to as low as $4.40 in May. It closed June 21 at about $7.22.\nIt’s still not huge, a market cap of $2.01 billion. But this is also, still, a small company, with March quarter revenue of just$3.1 million.\nBionano is a complete speculation. Is it a worthwhile one?\nWhat Redditors Got With BNGO Stock\nBionano is built around a device calledSaphyr.It does optical genome mapping and costs about$150,000. Then there are “consumables,” reagents for making tests. Bionano also sells testing as a service at about $1,000 per test.\nSaphyr does not yet have FDA approval, although that doesn’t matter outside the U.S. It’s used incytogenetics research, a market that management thinkscould be worth $700 million to $1 billion/year.\nBTIG, a Singapore-based investment company,began flogging Bionano recently. AnalystSung Ji Nam, who has dozens of buy recommendations out on various biotechs, wrote that Saphyr promises “higher accuracy and superior workflow efficiency” when compared with other mapping techniques. She highlighted three recent overseas contracts and a California study that spotted 18% more genetic diseases than conventional testing.\nThis means it’s not just the pajama traders who think Bionano has something. All four analysts following BNGO stock as tracked byTiprankshave it rated as a buy, with a price target of$11. That’s 51% higher than its present price, although still well short of where the Reddit speculation took it.\nBurning Cash\nBionano only came public at the start of the year and currently trades near the level of its first trade.\nThe March quarter report looked good, although the numbers we’re talking about are small.\nThe company reported product sales of $2.05 million, which comes toa little over a dozen machines. Services and reagents brought in another $1.11 million.\nBut Bionano is still burning cash. It spent $2.67 million on research during the quarter, and another $9.5 million on selling and administration. The net result was a loss of nearly $10 million, but that was just 4 cents per share. Bionano had 263 million shares outstanding after going public.\nThe good news is Bionano now has $362 million in cash, and less than $15 million in long-term debt. The bad news is that you’re paying over 160 times revenue. Even with a 162% growth rate, that’s rich. If Bionano hits its target of installing150 systems this year, that’s still just $22.5 million. Even the most optimistic analyst sees revenue of$36 million for 2022and continuing losses.\nThe Bottom Line\nBionano is on the cutting edge of the DNA sequencing market. This is indeed a huge opportunity, as DNA evolves intosomething like a programming language.Within its niche, Bionano faces strong competition from companies likePacific Biosciences&nbsp;(NASDAQ:PACB).\nI would like to seemore than a short squeezebefore recommending a stock. Our Muslim Farooque ishesitant to step inat Bionano’s current price.\nMy view is that if you believe Bionano Genomics has a viable solution and can sell in quantity, the current price of the stock is irrelevant. The problem is that I don’t know the answer to that question.\nAs I said at the onset, this is pure speculation. But unlike most of what I see onReddit, it’s not unreasonable speculation. Throw some money at Bionano if you want but know it will take years to learn whether you’ve hit bingo on BNGO.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics: Did Reddit Squirrels Find a Nut?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics: Did Reddit Squirrels Find a Nut?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 17:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/bionano-genomics-did-reddit-squirrels-find-a-nut/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nBNGO stock has been pushed this year by both Wall Street pros and meme stock amateurs.\n\nWhenever I see a stock trending on ther/WallStreetBetssubreddit, I get suspicious. Anyone can post there. They ...\n\n<a href=\"https://investorplace.com/2021/06/bionano-genomics-did-reddit-squirrels-find-a-nut/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/06/bionano-genomics-did-reddit-squirrels-find-a-nut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128318249","content_text":"BNGO stock has been pushed this year by both Wall Street pros and meme stock amateurs.\n\nWhenever I see a stock trending on ther/WallStreetBetssubreddit, I get suspicious. Anyone can post there. They can say anything. There’s the reputation for pushing short-squeezes on failing companies. There’s just no credibility.\nSource: Marcus Krauss / Shutterstock.com\nCase in point, a small company calledBionano Genomics(NASDAQ:BNGO), which in February gota push from the WSB crowd. It started as BNGO stock was selling at about $10 a share. It quickly jumped to $15. Then it fell, to as low as $4.40 in May. It closed June 21 at about $7.22.\nIt’s still not huge, a market cap of $2.01 billion. But this is also, still, a small company, with March quarter revenue of just$3.1 million.\nBionano is a complete speculation. Is it a worthwhile one?\nWhat Redditors Got With BNGO Stock\nBionano is built around a device calledSaphyr.It does optical genome mapping and costs about$150,000. Then there are “consumables,” reagents for making tests. Bionano also sells testing as a service at about $1,000 per test.\nSaphyr does not yet have FDA approval, although that doesn’t matter outside the U.S. It’s used incytogenetics research, a market that management thinkscould be worth $700 million to $1 billion/year.\nBTIG, a Singapore-based investment company,began flogging Bionano recently. AnalystSung Ji Nam, who has dozens of buy recommendations out on various biotechs, wrote that Saphyr promises “higher accuracy and superior workflow efficiency” when compared with other mapping techniques. She highlighted three recent overseas contracts and a California study that spotted 18% more genetic diseases than conventional testing.\nThis means it’s not just the pajama traders who think Bionano has something. All four analysts following BNGO stock as tracked byTiprankshave it rated as a buy, with a price target of$11. That’s 51% higher than its present price, although still well short of where the Reddit speculation took it.\nBurning Cash\nBionano only came public at the start of the year and currently trades near the level of its first trade.\nThe March quarter report looked good, although the numbers we’re talking about are small.\nThe company reported product sales of $2.05 million, which comes toa little over a dozen machines. Services and reagents brought in another $1.11 million.\nBut Bionano is still burning cash. It spent $2.67 million on research during the quarter, and another $9.5 million on selling and administration. The net result was a loss of nearly $10 million, but that was just 4 cents per share. Bionano had 263 million shares outstanding after going public.\nThe good news is Bionano now has $362 million in cash, and less than $15 million in long-term debt. The bad news is that you’re paying over 160 times revenue. Even with a 162% growth rate, that’s rich. If Bionano hits its target of installing150 systems this year, that’s still just $22.5 million. Even the most optimistic analyst sees revenue of$36 million for 2022and continuing losses.\nThe Bottom Line\nBionano is on the cutting edge of the DNA sequencing market. This is indeed a huge opportunity, as DNA evolves intosomething like a programming language.Within its niche, Bionano faces strong competition from companies likePacific Biosciences (NASDAQ:PACB).\nI would like to seemore than a short squeezebefore recommending a stock. Our Muslim Farooque ishesitant to step inat Bionano’s current price.\nMy view is that if you believe Bionano Genomics has a viable solution and can sell in quantity, the current price of the stock is irrelevant. The problem is that I don’t know the answer to that question.\nAs I said at the onset, this is pure speculation. But unlike most of what I see onReddit, it’s not unreasonable speculation. Throw some money at Bionano if you want but know it will take years to learn whether you’ve hit bingo on BNGO.","news_type":1},"isVote":1,"tweetType":1,"viewCount":29,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/129306379"}